Comment on: EBRT plus brachytherapy stands out for high-risk prostate cancer

Comment on: Venetoclax, inotuzumab ozogamicin promising in older leukemia patients

Advisory board member Krishnansu Tewari comments on the phase III trial of HIPEC in epithelial ovarian cancer, published in NEJM.

Advisory board member Fiona Blackhall comments on The BMJ study showing no survival, QoL gain for many EMA cancer drug approvals.

Summary of Science Translational Medicine article covered in: Mutation-directed CAR T cell therapy feasible in recurrent glioblastoma

Our international Editorial Board provides expert commissioning guidance and insight into their specific topic areas to the in-house editorial team.

Our international Advisory Board provides additional support and expert insight into specific topic areas to the Editorial Board and in-house editorial team.

Our international Advisory Board works closely with our editorial team to highlight gaps in coverage and select topics to feature on this digital platform.

The HSDs went through several iterations over the course of a year, in collaboration with a highly engaged community advisory board, laying the groundwork for HSDs that are comprehensible, comparable, and appropriate for stated-preference research.

WATCH  |   Advisory Board member Ross Camidge shares his top picks of the presentations at the 2019 World Conference on Lung Cancer, including the CASPIAN trial and the updated AMG 510 data (1:51).

Advisory Board member Ross Camidge comments on his picks for the most exciting lung cancer research being presented at the 2019 ASCO Annual Meeting, including the RELAY trial and the ARROW trial of the RET inhibitor BLU-667 (3:13).

Advisory board member and study author Lecia Sequist takes us through the findings of the savolitinib plus osimertinib cohort of the phase Ib TATTON trial of advanced non-small-cell cancer patients who have developed resistance to EGFR inhibitor therapy (4:48).

Presenting author Ramaswamy Govindan outlines the key findings of the non-small-cell lung cancer cohort of the trial and the next steps for the research (5:34): Govidan video Advisory Board member Ross Camidge discusses the implications of this trial in his round-up of key data presented at WCLC 2019: Camidge video

Advisory Board member Ross Camidge takes us through the latest research on ALK inhibitors and other targeted therapies for lung cancer, including updated data from the ALEX trial (8:46).

Watch this video to find out which studies reported at the ASCO Annual Meeting 2018 caught the interest of Advisory board member Lecia Sequist. She also talks about her own research presented at the conference (6:38).

This edition of the medwireNews podcast focuses on a recent trial of the MEK inhibitor selumetinib in metastatic uveal melanoma. Advisory Board member and study author Paul Nathan outlines the findings and discusses the wider implications.

This edition of the medwireNews podcast focuses on a recent trial of the MEK inhibitor selumetinib in metastatic uveal melanoma. Advisory Board member and study author Paul Nathan outlines the findings and discusses the wider implications.

External beam radiotherapy plus brachytherapy and radical prostatectomy are both suitable options for men with high-risk prostate cancer, while EBRT–BT appears to be the optimal regimen for Gleason score 9–10 disease, indicate the results of two studies. Click here for a commentary by advisory board member Axel Merseburger.

And in a comment to medwireNews , Medicine Matters oncology Advisory Board member Ross Camidge (University of Colorado Cancer Center, Aurora, USA) questioned the relevance of the trial results given that erlotinib is no longer the preferential agent for first-line treatment in these patients, having been superseded by osimertinib.

Immunotherapy is changing practice in lung cancer, and with this, patient education. In this 'View from the clinic' article, Advisory Board member  Beth Eaby-Sandy (Abramson Cancer Center, PA, USA)  describes how she explains the new immunotherapy treatments to her patients.